0.470.371.311.2910261001252101077843482315544111698261423690001844392--12-312021Q3falseP5Y000.200001844392mrai:MarpaiWarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-09-300001844392mrai:MarpaiWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-09-300001844392mrai:MarpaiWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-09-300001844392mrai:MarpaiWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-09-300001844392mrai:MarpaiWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-09-300001844392mrai:MarpaiWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2021-09-300001844392mrai:MarpaiHealthWarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-09-300001844392mrai:MarpaiHealthWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-09-300001844392mrai:MarpaiHealthWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-09-300001844392mrai:MarpaiHealthWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-09-300001844392mrai:MarpaiHealthWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-09-300001844392mrai:MarpaiHealthWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2021-09-300001844392mrai:ContinentalBenefitsLlcMember2021-01-152021-01-1500018443922019-07-012019-09-3000018443922019-01-012019-09-300001844392us-gaap:CommonStockMember2021-07-012021-09-300001844392us-gaap:SubsequentEventMemberus-gaap:OverAllotmentOptionMember2021-10-262021-10-260001844392us-gaap:SubsequentEventMemberus-gaap:IPOMember2021-10-262021-10-2600018443922021-09-022021-09-020001844392us-gaap:RetainedEarningsMember2021-09-300001844392us-gaap:AdditionalPaidInCapitalMember2021-09-300001844392us-gaap:RetainedEarningsMember2021-06-300001844392us-gaap:AdditionalPaidInCapitalMember2021-06-3000018443922021-06-300001844392us-gaap:RetainedEarningsMember2020-12-310001844392us-gaap:AdditionalPaidInCapitalMember2020-12-310001844392us-gaap:RetainedEarningsMember2020-09-300001844392us-gaap:AdditionalPaidInCapitalMember2020-09-300001844392us-gaap:RetainedEarningsMember2020-06-300001844392us-gaap:AdditionalPaidInCapitalMember2020-06-3000018443922020-06-300001844392us-gaap:RetainedEarningsMember2019-12-310001844392us-gaap:AdditionalPaidInCapitalMember2019-12-310001844392mrai:MarpaiWarrantsMember2021-02-280001844392us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001844392us-gaap:EmployeeStockOptionMember2020-12-310001844392us-gaap:EmployeeStockOptionMember2020-09-300001844392us-gaap:RestrictedStockMember2020-12-310001844392us-gaap:RestrictedStockMember2020-09-300001844392us-gaap:RestrictedStockMember2019-12-310001844392us-gaap:SubsequentEventMember2021-11-022021-11-020001844392us-gaap:LeaseholdImprovementsMember2021-01-012021-09-300001844392us-gaap:FurnitureAndFixturesMember2021-01-012021-09-300001844392us-gaap:EquipmentMember2021-01-012021-09-300001844392us-gaap:LeaseholdImprovementsMember2021-09-300001844392us-gaap:FurnitureAndFixturesMember2021-09-300001844392us-gaap:EquipmentMember2021-09-300001844392us-gaap:LeaseholdImprovementsMember2020-12-310001844392us-gaap:FurnitureAndFixturesMember2020-12-310001844392us-gaap:EquipmentMember2020-12-310001844392us-gaap:SubsequentEventMember2021-10-042021-10-0400018443922021-10-282021-10-280001844392us-gaap:StateAndLocalJurisdictionMember2020-12-310001844392us-gaap:DomesticCountryMember2020-12-310001844392country:US2021-09-300001844392country:IL2021-09-300001844392country:US2020-12-310001844392country:IL2020-12-310001844392us-gaap:RetainedEarningsMember2021-07-012021-09-300001844392us-gaap:RetainedEarningsMember2021-01-012021-09-300001844392us-gaap:RetainedEarningsMember2020-07-012020-09-300001844392us-gaap:RetainedEarningsMember2020-01-012020-09-3000018443922021-07-290001844392mrai:EymeTechnologiesLtdMember2021-09-300001844392srt:MinimumMember2021-09-300001844392srt:MaximumMember2021-09-300001844392us-gaap:TrademarksMember2021-01-012021-09-300001844392us-gaap:OtherIntangibleAssetsMember2021-01-012021-09-300001844392us-gaap:CustomerRelationshipsMember2021-01-012021-09-300001844392us-gaap:ComputerSoftwareIntangibleAssetMember2021-01-012021-09-300001844392srt:MinimumMember2021-01-012021-09-300001844392srt:MaximumMember2021-01-012021-09-300001844392us-gaap:PatentsMember2021-09-300001844392us-gaap:ComputerSoftwareIntangibleAssetMember2021-01-012021-09-300001844392mrai:IntangibleAssetsOtherThanCapitalizedSoftwareMember2021-01-012021-09-300001844392mrai:ContinentalBenefitsLlcMemberus-gaap:PatentsMember2021-01-012021-09-300001844392us-gaap:TrademarksMember2021-09-300001844392us-gaap:OtherIntangibleAssetsMember2021-09-300001844392us-gaap:CustomerRelationshipsMember2021-09-300001844392mrai:MarpaiHealthWarrantsMember2021-01-012021-09-300001844392us-gaap:EmployeeStockOptionMember2021-09-300001844392us-gaap:RestrictedStockMember2021-09-300001844392mrai:ConvertibleNotes2020Member2020-12-310001844392mrai:PurchaseNoteMember2019-10-240001844392us-gaap:CommonStockMember2021-09-300001844392us-gaap:CommonStockMember2021-06-300001844392us-gaap:CommonStockMember2020-12-310001844392us-gaap:CommonStockMember2020-09-300001844392us-gaap:CommonStockMember2020-06-300001844392us-gaap:CommonStockMember2019-12-310001844392us-gaap:SubsequentEventMemberus-gaap:IPOMember2021-10-260001844392mrai:MarpaiHealthWarrantsMember2021-04-010001844392srt:MinimumMembermrai:MarpaiWarrantsMember2021-09-300001844392srt:MaximumMembermrai:MarpaiWarrantsMember2021-09-300001844392mrai:MarpaiWarrantsMember2021-07-310001844392mrai:MarpaiWarrantsMember2021-04-300001844392mrai:MarpaiHealthWarrantsMember2021-02-280001844392mrai:MarpaiHealthWarrantsMember2020-01-1700018443922019-12-3100018443922020-09-300001844392mrai:MarpaiHealthMember2021-04-010001844392mrai:ContinentalBenefitsLlcMemberus-gaap:TrademarksMember2021-04-010001844392mrai:ContinentalBenefitsLlcMemberus-gaap:PatentsMember2021-04-010001844392mrai:ContinentalBenefitsLlcMemberus-gaap:OtherIntangibleAssetsMember2021-04-010001844392mrai:ContinentalBenefitsLlcMemberus-gaap:CustomerRelationshipsMember2021-04-010001844392mrai:ContinentalBenefitsLlcMemberus-gaap:ComputerSoftwareIntangibleAssetMember2021-04-010001844392mrai:ContinentalBenefitsLlcMember2021-04-012021-04-0100018443922020-01-012020-12-310001844392us-gaap:RestrictedStockMember2021-07-012021-09-300001844392us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001844392us-gaap:RestrictedStockMember2021-01-012021-09-300001844392us-gaap:RestrictedStockMember2020-07-012020-09-300001844392us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001844392us-gaap:RestrictedStockMember2020-01-012020-09-300001844392us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001844392mrai:MarpaiWarrantsMember2021-04-012021-04-300001844392mrai:MarpaiHealthWarrantsMember2021-02-012021-02-280001844392us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001844392us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001844392us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-3000018443922020-07-012020-09-300001844392us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001844392mrai:ContinentalBenefitsLlcMemberus-gaap:TrademarksMember2021-01-012021-09-300001844392mrai:ContinentalBenefitsLlcMemberus-gaap:OtherIntangibleAssetsMember2021-01-012021-09-300001844392mrai:ContinentalBenefitsLlcMemberus-gaap:CustomerRelationshipsMember2021-01-012021-09-300001844392mrai:MarpaiWarrantsMember2020-12-310001844392mrai:MarpaiWarrantsMember2020-09-300001844392srt:MinimumMembermrai:MarpaiWarrantsMember2021-01-012021-09-300001844392srt:MaximumMembermrai:MarpaiWarrantsMember2021-01-012021-09-300001844392mrai:MarpaiWarrantsMember2020-01-012020-09-300001844392mrai:MarpaiWarrantsMember2021-01-012021-09-3000018443922021-07-292021-07-290001844392us-gaap:CommonStockMember2021-01-012021-09-300001844392us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001844392mrai:June2021NotesMember2021-06-300001844392mrai:ConvertibleNotes2021Member2021-03-310001844392mrai:ConvertibleNotesThirdTrancheMember2020-12-310001844392mrai:ConvertibleNotesSecondTrancheMember2020-12-310001844392mrai:ConvertibleNotesFirstTrancheMember2020-12-310001844392mrai:ConvertibleNotes2019Member2019-12-310001844392mrai:ConvertibleNotesThirdTrancheMember2020-01-012020-12-310001844392mrai:ConvertibleNotesSecondTrancheMember2020-01-012020-12-310001844392mrai:ConvertibleNotesFirstTrancheMember2020-01-012020-12-310001844392mrai:ContinentalBenefitsLlcMember2021-01-222021-01-220001844392mrai:PurchaseNoteMember2019-10-242019-10-240001844392mrai:ConvertibleNotes2019Member2019-01-012019-12-310001844392mrai:EymeTechnologiesLtdMember2019-08-012019-08-010001844392mrai:EymeTechnologiesLtdMember2021-01-012021-09-300001844392mrai:ConvertibleNotes2021Member2021-02-012021-03-3100018443922020-01-012020-09-300001844392us-gaap:ComputerSoftwareIntangibleAssetMember2021-09-300001844392mrai:IntangibleAssetsOtherThanCapitalizedSoftwareMember2021-09-3000018443922021-07-012021-09-300001844392mrai:June2021NotesMember2021-06-012021-06-300001844392mrai:ConvertibleNotes2020Member2020-01-012020-12-310001844392mrai:ConvertibleNotes2020AndConvertibleNotes2021Member2021-01-012021-09-300001844392us-gaap:SubsequentEventMember2021-10-262021-10-260001844392mrai:MarpaiHealthsConvertibleNotesMember2021-01-012021-09-300001844392mrai:ConvertibleNotes2020Member2021-01-012021-09-300001844392mrai:ConvertibleNotes2019Member2021-01-012021-09-3000018443922020-12-310001844392mrai:ContinentalBenefitsLlcMember2021-04-010001844392mrai:MarpaiHealthMember2021-04-012021-04-0100018443922021-09-3000018443922021-12-0900018443922021-01-012021-09-30xbrli:sharesiso4217:USDxbrli:puremrai:itemmrai:customeriso4217:USDxbrli:sharesmrai:segmentmrai:Y

Table of Contents`

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

or

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to

Commission File Number: 001-40904

"

MARPAI, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

    

86-1916231

(State or other jurisdiction
of incorporation)

 

(IRS Employer
Identification Number)

5701 East Hillsborough Ave., Suite 1417

Tampa, Florida 33610-5428

(Address of principal executive offices)

(646) 303-3483

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

MRAI

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of December 9, 2021, there were 20,122,896 shares of the Company’s common stock, par value $0.0001 per share outstanding.

Table of Contents`

MARPAI, INC.

TABLE OF CONTENTS

Page

PART I. FINANCIAL INFORMATION

Item 1.

Unaudited Condensed Consolidated Financial Statements

1

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

30

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

37

Item 4.

Controls and Procedures

37

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

39

Item 1A.

Risk Factors

39

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

39

Item 3.

Defaults Upon Senior Securities

40

Item 4.

Mine Safety Disclosures

40

Item 5.

Other Information

40

Item 6.

Exhibits

41

SIGNATURES

42

i

Table of Contents`

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

MARPAI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

September 30, 2021

    

(Unaudited)

    

December 31, 2020

ASSETS:

  

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

1,190,974

$

1,754,569

Restricted cash

 

7,809,679

 

63,363

Accounts receivable

 

299,849

 

Unbilled receivable

 

37,863

 

Prepaid expenses and other current assets

 

774,362

 

262,211

Other receivables

 

52,836

 

100,038

Total current assets

 

10,165,563

 

2,180,181

Property and equipment, net

 

720,592

 

195,404

Capitalized software, net

 

6,617,382

 

3,818,959

Operating lease right-of-use assets

 

1,546,495

 

337,316

Goodwill

 

1,676,239

 

Intangible assets, net

 

6,503,301

 

Security deposits

 

52,277

 

Total assets

$

27,281,849

$

6,531,860

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

2,651,216

$

159,168

Accounts payable – related party

 

 

15,725

Accrued expenses

 

1,932,992

 

267,967

Accrued fiduciary obligations

 

5,063,949

 

Deferred revenue

 

1,352,221

 

Current portion of operating lease liabilities

 

713,792

 

96,472

Current portion of convertible notes payable

 

999,326

 

1,866,237

Short-term loan

 

2,011,250

 

Due to related party

 

3,637

 

243,638

Total current liabilities

 

14,728,383

 

2,649,207

Convertible notes payable, net of current portion

 

4,865,526

 

7,095,887

Other long-term liabilities

 

45,000

 

Operating lease liabilities, net of current portion

 

1,027,148

 

283,265

Deferred tax liabilities

 

2,001,012

 

Total liabilities

 

22,667,069

 

10,028,359

COMMITMENTS AND CONTINGENCIES

 

  

 

  

STOCKHOLDERS’ EQUITY (DEFICIT)

 

  

 

  

Common stock, $0.0001 par value, 227,791,050 shares authorized; 11,169,826 issued and outstanding at September 30, 2021 and 142,369 issued and outstanding at December 31, 2020 (1)

 

1,117

 

14

Additional paid-in capital

 

20,410,705

 

2,044,362

Accumulated deficit

 

(15,797,042)

 

(5,540,875)

Total stockholders’ equity (deficit)

 

4,614,780

 

(3,496,499)

Total liabilities and stockholders’ equity (deficit)

$

27,281,849

$

6,531,860

(1)Reflects 4.555821-for-1 forward split that became effective September 2, 2021. See Note 17 to the condensed consolidated financial statements.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three months ended September 30, 

Nine months ended September 30, 

    

2021

    

2020

    

2021

    

2020

Revenue

$

4,799,251

$

$

8,330,763

$

Costs and expenses

 

  

 

  

 

  

 

  

Cost of revenue (exclusive of depreciation and amortization shown separately below)

 

3,343,196

 

 

6,063,679

 

General and administrative

 

2,229,809

 

280,557

 

5,044,759

 

1,053,780

Sales and marketing

 

1,588,981

 

21,960

 

3,032,766

 

27,583

Information technology

 

770,124

 

 

1,501,354

 

Research and development

 

568,817

 

470,943

 

1,118,191

 

1,496,929

Depreciation and amortization

 

802,240

 

18,362

 

1,223,207

 

56,246

Facilities

 

231,841

 

 

458,733

 

Total costs and expenses

 

9,535,008

 

791,822

 

18,442,689

 

2,634,538

Operating loss

 

(4,735,757)

 

(791,822)

 

(10,111,926)

 

(2,634,538)

Other income (expenses)

 

  

 

  

 

  

 

  

Other income

 

54,637

 

6,440

 

109,063

 

19,178

Interest expense

 

(108,503)

 

(137,992)

 

(384,564)

 

(364,327)

Foreign exchange loss

 

(2,956)

 

(2,890)

 

(18,740)

 

(5,079)

Loss before provision for income taxes

 

(4,792,579)

 

(926,264)

 

(10,406,167)

 

(2,984,766)

Income tax benefit

 

 

 

(150,000)

 

Net loss

$

(4,792,579)

$

(926,264)

$

(10,256,167)

$

(2,984,766)

Net loss per share, basic & fully diluted(1)

$

(0.47)

$

(0.37)

$

(1.31)

$

(1.29)

Weighted average number of common shares, basic and fully diluted(1)

 

10,261,001

 

2,521,010

 

7,846,348

 

2,315,544

(1)Reflects 4.555821-for-1 forward split that became effective September 2, 2021. The computation of basis and diluted net loss per share was retroactively adjusted for all periods presented. See Note 17 to the condensed consolidated financial statements.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

Common Stock

  

  

  

Additional Paid-

Accumulated

Total Stockholders’

    

Shares

    

Amount

    

In Capital

    

Deficit

    

Equity (Deficit)

Three months ended September 30, 2020

 

  

 

  

 

  

 

  

 

  

Balance, July 1, 2020

 

142,369

$

14

$

1,655,069

$

(3,731,393)

$

(2,076,310)

Share-based compensation

 

 

 

194,647

 

 

194,647

Net loss

 

 

 

 

(926,264)

 

(926,264)

Balance, September 30, 2020 (Unaudited)

 

142,369

$

14

$

1,849,716

$

(4,657,657)

$

(2,807,927)

Three months ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

Balance, July 1, 2021

 

11,147,302

$

1,115

$

20,154,521

$

(11,004,463)

$

9,151,173

Stock options exercised

 

22,524

 

2

 

47

 

 

49

Share-based compensation

 

 

 

256,137

 

 

256,137

Net loss

 

 

 

 

(4,792,579)

 

(4,792,579)

Balance, September 30, 2021 (Unaudited)

 

11,169,826

$

1,117

$

20,410,705

$

(15,797,042)

$

4,614,780

Nine months ended September 30, 2020

 

  

 

  

 

  

 

  

 

  

Balance, January 1, 2020

 

142,369

$

14

$

799,732

$

(1,672,891)

$

(873,145)

Fair value of warrants issued with convertible note

 

 

 

213,828

 

 

213,828

Share-based compensation

 

 

 

836,156

 

 

836,156

Net loss

 

 

 

 

(2,984,766)

 

(2,984,766)

Balance, September 30, 2020 (Unaudited)

 

142,369

$

14

$

1,849,716

$

(4,657,657)

$

(2,807,927)

Nine months ended September 30, 2021

 

  

 

  

 

  

 

  

 

  

Balance, January 1, 2021

 

142,369

$

14

$

2,044,362

$

(5,540,875)

$

(3,496,499)

Exchange of common shares of Marpai Health, Inc. (see Note 1)

 

(142,369)

 

(14)

 

 

 

(14)

Issuance of common shares of Marpai, Inc. (see Note 1)

 

11,147,302

 

1,115

 

17,350,820

 

 

17,351,935

Stock options exercised

 

22,524

 

2

 

47

 

 

49

Warrants issued for cash

 

 

 

53,333

 

 

53,333

Share-based compensation

 

 

 

962,143

 

 

962,143

Net loss

 

 

 

 

(10,256,167)

 

(10,256,167)

Balance, September 30, 2021 (Unaudited)

 

11,169,826

$

1,117

$

20,410,705

$

(15,797,042)

$

4,614,780

(1)Reflects 4.555821-for-1 forward split that became effective September 2, 2021. See Note 17 to the condensed consolidated financial statements

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine months ended September 30, 

    

2021

    

2020

Cash flows from operating activities:

 

  

 

  

Net loss

$

(10,256,167)

$

(2,984,766)

Adjustments to reconcile net loss to net cash used in operating activities:

 

  

 

  

Depreciation and amortization

 

1,223,207

 

56,246

Share-based compensation

 

962,143

 

836,156

Amortization of right-of-use asset

 

42,799

 

57,798

Amortization of debt discount

 

26,728

 

75,300

Non-cash interest

 

352,171

 

285,835

Convertible note issued for professional services

 

75,000

 

Deferred taxes

 

(150,000)

 

Changes in operating assets and liabilities:

 

  

 

  

(Increase) in accounts receivable and unbilled receivable

 

(245,481)

 

(Increase) in prepaid expense and other assets

 

(380,738)

 

(106,442)

Decrease in other receivable

 

47,202

 

Decrease in security deposit

 

2,592

 

Increase in accounts payable

 

1,566,439

 

70,023

(Decrease) increase in accounts payable – related party

 

(15,725)

 

15,725

Increase in accrued expenses

 

397,317

 

112,573

Increase in accrued fiduciary obligations

 

993,041

 

(Decrease) in operating lease liabilities

 

(74,096)

 

(64,539)

(Decrease) in due to related party

 

(240,001)

 

Increase in other liabilities

 

147,001

 

Net cash used in operating activities

 

(5,526,568)

 

(1,646,091)

Cash flows from investing activities:

 

  

 

  

Cash and restricted cash acquired as part of Acquisition (see Note 4)

 

11,384,035

 

Capitalization of software development costs

 

(1,211,511)

 

(140,104)

Purchase of property and equipment

 

(66,617)

 

(32,067)

Reimbursement of leasehold improvements from sublease

 

 

45,640

Net cash provided by (used in) investing activities

 

10,105,907

 

(126,531)

Cash flows from financing activities:

 

  

 

  

Proceeds from stock option exercises

 

49

 

Proceeds from convertible notes

 

550,000

 

2,000,000

Proceeds from short-term loan

 

2,000,000

 

Proceeds from issuance of warrants

 

53,333

 

Net cash provided by financing activities

 

2,603,382

 

2,000,000

Net increase in cash, cash equivalents and restricted cash

 

7,182,721

 

227,378

Cash, cash equivalents and restricted cash at beginning of period

 

1,817,932

 

246,277

Cash, cash equivalents and restricted cash at end of period

$

9,000,653

$

473,655

Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheet

 

  

 

  

Cash and cash equivalents

$

1,190,974

$

414,455

Restricted cash

 

7,809,679

 

59,200

Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows

$

9,000,653

$

473,655

Supplemental disclosure of non-cash activity

 

  

 

  

Conversion of convertible notes into common stock at the closing of the Acquisition

$

4,174,992

$

Common stock issued as part of the Acquisition

$

8,500,000

$

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization

Marpai, Inc. (“Marpai”) was formed as a Delaware corporation on January 22, 2021 with the intention to facilitate an initial public offering (“IPO”) and other related transactions in order to carry on the business of two healthcare subsidiaries, Marpai Health, Inc. (“Marpai Health”) and Continental Benefits LLC (“Continental Benefits”).

Marpai Health, a Delaware corporation, was incorporated on February 14, 2019. On March 21, 2019, EYME Technologies Ltd. (“EYME”), a wholly owned subsidiary of Marpai Health located in Israel, was formed. Marpai Health, along with its wholly owned subsidiary, EYME, are hereinafter referred to as the “Marpai Health”.

On April 1, 2021, pursuant to the terms of the Amended and Restated Equity Interest Purchase and Reorganization Agreement, as was further addended on May 7, 2021 (collectively, the “Agreement”), the stockholders of the Marpai Health and the sole member of Continental Benefits, LLC contributed their respective shares and ownership interests in Marpai Health and Continental Benefits to Marpai in consideration for shares of the Marpai’s Class A and Class B common stock. Additionally, options to purchase 1,027,602 shares of Marpai Health’s common stock and warrants to purchase 1,366,746 shares of Marpai Health’s common stock were exchanged, on a one-to-one basis, for options and warrants to purchase shares of Marpai’s common stock (the above transactions are hereinafter referred to as the “Acquisition”). As part of the Acquisition, approximately $3,800,000 of Marpai Health’s convertible promissory notes were exchanged for shares of common stock of Marpai immediately prior to the Acquisition. As part of the Acquisition, pursuant to a note exchange agreement, Marpai acquired Marpai Health’s certain outstanding convertible promissory notes, with aggregate outstanding principal and accrued but unpaid interest of $2,198,459, in exchange for the issuance of Marpai’s convertible promissory notes of equivalent aggregate principal amount. The Agreement called for Continental Benefits to not have less than $4.762 million of cash on hand, and to have no debt at the time of closing of the Acquisition.

For accounting purposes, Continental Benefits was considered the acquiree and Marpai Health was considered the acquirer. The acquisition was accounted for using the acquisition method of accounting. See Notes 3 and 4 for additional information.

Marpai, along with its subsidiaries, Marpai Health and Continental Benefits, are hereinafter referred to as the “Company”.

Nature of Business

The Company’s mission is to positively change healthcare for the benefit of (i) its clients who are self-insured employers that pay for their employees’ healthcare benefits and engage the Company to administer the latter’s healthcare claims, (ii) employees who receive these healthcare benefits from its clients, and (iii) healthcare providers including, doctors, doctor groups, hospitals, clinics, and any other entities providing healthcare services or products. The Company’s operations are conducted through its wholly owned subsidiaries Marpai Health and Continental Benefits.

Marpai Health is engaged in developing artificial intelligence and healthcare technology that enables the analysis of data to predict and prevent costly events related to diagnostic errors, hospital visits and administrative issues.

Continental Benefits and its wholly owned subsidiary WellSystems, LLC (“WellSystems”) provide benefits outsourcing services to clients in the United States across multiple industries. Continental Benefits’ backroom administration and third-party administration (“TPA”) services are supported by a customized technology platform and a dedicated benefits call center. Under its TPA platform, Continental Benefits provides health and welfare administration, dependent eligibility verification, Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, and benefit billing services. Continental Benefits and WellSystems are Florida limited liability companies.

5

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS (CONTINUED)

Continental Benefits provides the technology platform, consisting of fully integrated billing and enrollment, claims administration, and customer service to administer the TPA services. Continental Benefits engages primarily in selling and customer relationship activities for supported clients.

The recent global pandemic outbreak, or COVID-19, continues to adversely impact commercial activity, globally and in the United States, and has contributed to significant volatility in financial markets. The outbreak could have a continued adverse impact on economic and market conditions, including business and financial services disruption. As of the date these condensed consolidated financial statements were available to be issued, the effects of impact are unknown and the Company will continue to monitor the potential impact of COVID-19 on the Company’s condensed consolidated financial statements.

NOTE 2 – LIQUIDITY

The accompanying condensed consolidated financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements as of the period ended September 30, 2021, the Company has an accumulated deficit of $15,797,042 and working capital deficit of $4,562,820. At September 30, 2021, the Company had total debt of $7,876,102 and $1,190,974 of unrestricted cash on hand. Since inception, the Company has met its cash needs through proceeds from issuing convertible notes and warrants. The Company’s current capital requirements are to fund working capital and operating activities, fund capital expenditures, and debt repayments.

On October 28, 2021 the Company received $24.8 million of net proceeds from an initial public offering (see Note 18). The Company believes cash on hand from the initial public offering will provide sufficient liquidity to fund operations for at least one year after the date these condensed consolidated financial statements are issued.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements and related notes are presented in accordance with generally accepted accounting principles in the United States (“GAAP”) and the requirements of the U.S. Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as its annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for the fair statement of the Company’s financial information. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2021, or for any other interim period or for any other future year. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, EYME and Marpai Health, for all the periods presented and Continental Benefits from April 1, 2021, the date of the Acquisition (see Note 4). All references to the Company and Marpai Health for periods prior to the Acquisition are interchangeable as if the Acquisition was in effect for all periods presented in the condensed consolidated financial statements and related notes. All significant intercompany balances and transactions have been eliminated in consolidation.

These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited financial statements for the years ended December 31, 2020 and for the period from February 14, 2019 (inception) to December 31, 2019 included in the prospectus filed on October 28, 2021 (the “Prospectus”).

6

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Business Combination

The Company accounts for business combinations in accordance with the Financial Accounting Standard Board’s (“FASB”) Accounting Standard Codification (“ASC”) 805, Business Combinations. Accordingly, identifiable tangible and intangible assets acquired and liabilities assumed are recorded at their estimated fair values, the excess of the purchase consideration over the fair values of net assets acquired is recorded as goodwill, and transaction costs are expensed as incurred.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, valuation of share-based compensation, accounting for warrants, allowance for doubtful accounts, useful lives of internally developed software, intangible assets and property and equipment, whether an arrangement is or contains a lease, the discount rate used for operating leases, income tax accruals, the valuation allowance for deferred income taxes, and the valuation of net assets acquired.

The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash consists of funds held in bank accounts. Cash equivalents consist of short-term, highly liquid investments with original maturities of 90 days or less at the time of purchase and generally include money market accounts.

Concentrations of Credit Risk

The Company maintains cash accounts with financial institutions. At times, balances in these accounts may exceed federally insured limits. The amounts over the federally insured limits as of September 30, 2021 and December 31, 2020 was approximately $926,000 and $1,505,000, respectively. No losses have been incurred to date on any deposit balances.

No customer accounted for greater than 10% of total revenue during for the nine months ended September 30, 2021. At September 30, 2021, four customers each accounted for greater than 10% of accounts receivable, respectively.

Restricted Cash

Restricted cash balances are composed of funds held on behalf of clients in a fiduciary capacity and cash held in a separate bank account pledged to a bank as collateral for a bank guarantee provided to the lessor to secure the Company’s obligations under its lease agreement. Fiduciary funds generally cannot be utilized for general corporate purposes and are not a source of liquidity for the Company. A corresponding fiduciary obligation, included in current liabilities in the accompanying condensed consolidated balance sheets, exists for disbursements to be made on behalf of the clients and may be more than the restricted cash balance if payment from customers has not been received.

7

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Accounts Receivable

Accounts receivable are recorded at the net invoiced amount, net of allowances for doubtful accounts, and do not bear interest. They include unbilled amounts for services rendered in the respective period but not yet billed to the customer, which typically occurs within one month.

The Company periodically reviews accounts receivable balances and provides an allowance for doubtful accounts to the extent deemed uncollectible. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in existing accounts receivable. The Company determines the allowance based on historical write-off experience and the aging of outstanding accounts receivable. Balances are considered past due based on invoiced terms. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company has determined that no allowance for doubtful accounts was necessary as of September 30, 2021.

Fair Value Measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), establishes a hierarchy of inputs used when available. Observable inputs are what market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are those that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

The three levels of the fair value hierarchy are described below:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3—Valuations that require inputs that are unobservable for the asset and liability in which there is little, if any, market activity.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments, which include accounts receivable, accounts payable, accrued expenses, and debt at fixed interest rates, approximate their fair values at September 30, 2021 and December 31, 2020, principally due to the short-term nature, maturities, or nature of interest rates of the above listed items.

Long-Lived Assets

The Company reviews its long-lived assets for impairment whenever events or circumstances exist that indicate the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets is measured by comparing the carrying amounts of the assets to the future undiscounted cash flows expected to be generated by the assets. If the asset or asset group is considered to be impaired, an impairment loss would be recorded to adjust the carrying amounts to the estimated fair value. Management has determined that no impairment of long-lived assets exists, and accordingly, no adjustments to the carrying amounts of the Company’s long-lived assets have been made for the nine months ended September 30, 2021 and 2020.

8

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Property and Equipment

Property and equipment consisting of office and computer equipment, furniture and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives.

    

Useful Lives

Equipment

3 years

Furniture and fixtures

 

5 years

Leasehold improvements

 

Shorter of 5 years or lease term

Capitalized Software

The Company complies with the guidance of ASC Topic 350-40, “Intangibles—Goodwill and Other—Internal Use Software”, in accounting for its internally developed system projects that it utilizes to provide its services to customers. These system projects generally relate to software of the Company that is not intended for sale or otherwise marketed. Internal and external costs incurred during the preliminary project stage are expensed as they are incurred. Once a project has reached the development stage, the Company capitalizes direct internal and external costs until the software is substantially complete and ready for its intended use. Costs for upgrades and enhancements are capitalized, whereas, costs incurred for maintenance are expensed as incurred. These capitalized software costs are amortized on a project-by- project basis over the expected economic life of the underlying software on a straight-line basis, which is generally three years. Amortization commences when the software is available for its intended use.

Goodwill

Goodwill is recognized and initially measured as any excess of the acquisition-date consideration transferred in a business combination over the acquisition-date amounts recognized for the net identifiable assets acquired. Goodwill is not amortized but is tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not result in an impairment of goodwill. The Company operates in one reporting segment and reporting unit; therefore, goodwill is tested for impairment at the consolidated level. First, the Company assesses qualitative factors to determine whether or not it is more likely than not that the fair value of a reporting unit is less than it’s carrying amount. If the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company conducts a quantitative goodwill impairment test comparing the fair value of the applicable reporting unit with its carrying value. If the carrying amount of the reporting unit exceeds the fair value of the reporting unit, the Company recognizes an impairment loss in the condensed consolidated statement of operations for the amount by which the carrying amount exceeds the fair value of the reporting unit. The Company performs its annual goodwill impairment test at December 31. No goodwill impairment triggering events were identified for the nine months ended September 30, 2021 and 2020.

9

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Intangible Assets

Intangible assets consist of customer relationships, non-compete agreements, and amounts attributed to patent and patent applications that were acquired through an acquisition and are amortized on a straight-line basis over useful lives ranging from five to ten years. The Company’s intangible assets are reviewed for impairment when events or circumstances indicate their carrying amount may not be recoverable. The Company reviews the recoverability of its intangible assets by comparing the carrying value of such assets to the related undiscounted value of the projected cash flows associated with the assets, or asset group. If the carrying value is found to be greater, the Company records an impairment loss for the excess of book value over fair value. No impairment of the Company’s intangible assets was recorded for the three and nine months ended September 30, 2021 and 2020.

Convertible Debt

The Company evaluates convertible debt to determine the impact (if any) of 1) embedded conversion option; 2) beneficial conversion feature; 3) bifurcation; 4) derivative liability; and 5) fair value adjustments and other expenses thereto. In assessing the convertible debt instruments, the Company determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC Topic 470, “Debt” (“ASC 470”), the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC Topic 815, “Derivatives and Hedging” (“ASC 815”).

Conventional convertible debt is a financial instrument in which the holder may only realize the value of the conversion option by exercising the option and receiving the entire proceeds in a fixed number of shares or the equivalent amount of cash. Conventional convertible debt, for which the fair value option is not elected at issuance, is accounted for as straight debt with no accounting recognition of the embedded equity option.

The convertible debt the Company issued has the following typical characteristics:

The debt security is convertible into the common stock of the issuer at a specified price or price that can be measured at the option of the holder.
The debt security was sold at a price or has a value at issuance not significantly in excess of the face amount.
It bears an interest rate that is lower than the Company would obtain for nonconvertible debt.
If converted, the Company must deliver shares of its stock to the investor (i.e., physical settlement). There is no cash conversion feature by which the convertible debt can be settled in full or in part in cash upon conversion.
The initial conversion price of the security is greater than the market value of the common stock at time of issuance and there is no beneficial conversion feature (“BCF”) upon issuance to be bifurcated and separately accounted for.

Since the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company accounts for convertible debt instruments in accordance with ASC 470-20, Debt with Conversion and Other Options.

10

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Income Taxes

The Company follows ASC Topic 740-10-65-1 in accounting for uncertainty in income taxes by prescribing rules for recognition, measurement, and classification in financial statements of tax positions taken or expected to be in a tax return. This prescribes a two-step process for the financial statement measurement and recognition of a tax position. The first step involves the determination of whether it is more likely than not (greater than 50 percent likelihood) that a tax position will be sustained upon examination, based on the technical merits of the position. The second step requires that any tax position that meets the more likely than not recognition threshold be measured and recognized in the financial statements at the largest amount of benefit that is a greater than 50 percent likelihood of being realized upon ultimate settlement. This topic also provides guidance on the accounting for related interest and penalties, financial statement classification and disclosure. The Company’s policy is that any interest or penalties related to uncertain tax positions are recognized in income tax expense when incurred. The Company has no uncertain tax positions or related interest or penalties requiring accrual at September 30, 2021 and December 31, 2020.

Revenue Recognition

Revenue is recognized when control of the promised services is transferred to the Company’s customers in an amount that reflects the consideration expected to be entitled to in exchange for those services. As the Company completes its performance obligations, which are identified below, it has an unconditional right to consideration, as outlined in the Company’s contracts.

Contract Balances

At September 30, 2021, the balances of the Company’s accounts receivable from contracts with customers were $299,849 and the balances of the Company’s unbilled receivables from contracts with customers were $37,863. When the Company receives consideration from a customer prior to transferring services to the customer under the terms of the customer contracts, it records deferred revenue on the Company’s condensed consolidated balance sheet, which represents a contract liability. At September 30, 2021, the balances of the deferred revenue were $1,352,221 and the Company had performance guarantee liabilities of $680,737 included in accrued expenses on the condensed consolidated balance sheet. The Company anticipates that it will satisfy all of its performance obligations associated with its contract liabilities within a year.

Significant Payment Terms

Generally, the Company’s accounts receivable are expected to be collected in 30 days in accordance with the underlying payment terms. Invoices for services performed over time are typically sent to customers on the last business day of each calendar month in arrears. The Company does not offer discounts if the customer pays some or all an invoiced amount prior to the due date.

Consideration paid for services rendered by the Company is nonrefundable. Therefore, at the time revenue is recognized, the Company does not estimate expected refunds for services.

The Company uses the practical expedient not to account for significant financing components because the period between recognition and collection does not exceed one year for most of the Company’s contracts.

11

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Timing of Performance Obligations

Most of the Company’s contracts with customers obligate the Company to perform services. Services provided include health and welfare administration, dependent eligibility verification, COBRA administration, and benefit billing. Revenue is recognized over time as services are provided as the performance obligations are satisfied through the effort expended to research, investigate, evaluate, document, and report claims, and control of these services is transferred to the customer. The Company has the right to receive payment for all services rendered.

Determining and Allocating the Transaction Price

The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer.

To determine the transaction price of a contract, the Company considers its customary business practices and the terms of the contract. For the purpose of determining transaction prices, the Company assumes that the services will be transferred to the customer as promised in accordance with existing contracts and that the contracts will not be canceled, renewed, or modified.

The Company’s contracts with customers have fixed fee prices that are denominated per employee per month. The Company includes amounts of variable consideration in a contract’s transaction price only to the extent that the Company has a relatively high level of confidence that the amounts will not be subject to significant reversals (that is, downward adjustments to revenue recognized for satisfied performance obligations). In determining amounts of variable consideration to include in a contract’s transaction price, the Company relies on its experience and other evidence that supports its qualitative assessment of whether revenue would be subject to a significant reversal. The Company considers all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur.

Share-Based Compensation

The Company accounts for share-based awards issued to employees in accordance with ASC Topic 718, “Compensation—Stock Compensation”. In addition, the Company issues stock options to non-employees in exchange for consulting services and accounts for these in accordance with the provisions of Accounting Standards Update (“ASU”) 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). Compensation expense is measured at the grant date, based on the calculated fair value of the award, and recognized as an expense over the requisite service period, which is generally the vesting period of the grant.

For modification of stock compensation awards, the Company records the incremental fair value of the modified award as share-based compensation on the date of modification for vested awards or over the remaining vesting period for unvested awards. The incremental compensation is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.

For options granted to non-employees, the expected life of the option used is the contractual term of each such option. All other assumptions used to calculate the grant date fair value are generally consistent with the assumptions used for options granted to employees.

12

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

For purposes of calculating share-based compensation, the Company estimates the fair value of stock options using a Black-Scholes option-pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the Company’s stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected volatility is primarily based on the historical volatility of peer company data while the expected life of the stock options is based on historical and other economic data trended into the future. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding to the expected option term. The dividend yield assumption is based on the Company’s history and expectation of no dividend payouts.

If factors change and the Company employs different assumptions, share-based compensation expense may differ significantly from what has been recorded in the past. If there is a difference between the assumptions used in determining share-based compensation expense and the actual factors which become known over time, specifically with respect to anticipated forfeitures, the Company may change the input factors used in determining share-based compensation costs for future grants. These changes, if any, may materially impact the Company’s results of operations in the period such changes are made. Incremental compensation costs arising from subsequent modifications of awards after the grant date are recognized when incurred. In addition, the Company accounts for forfeitures of awards as they occur. For share-based awards that vest based on performance conditions, expense is recognized when it is probable that the conditions will be met.

The fair value of options and share awards granted under the stock option plan during the nine months ended September 30, 2021 and 2020 was estimated at the date of grant using the Black-Scholes option pricing model and the following assumptions for grants:

    

2021

    

2020

 

Risk-free interest rates

0.912

%  

1.0261.399

%

Expected life

 

5 years

 

6.25 years

Expected volatility

 

40.81

%  

34.60

%

Expected dividend yield

 

0.00

%  

0.00

%

Foreign Currency Translation

For non-U.S. operations, the functional currency is U.S. dollars since these operations are a direct and integral component or extension of the parent company’s operations. As a result, the transactions of those operations that are denominated in foreign currencies are re-measured into U.S. dollars, and any resulting gains or losses are included in earnings.

Foreign Operations

Operations outside the United States include EYME. Foreign operations are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange.

Earnings Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of outstanding common shares for the period, considering the effect of participating securities. Diluted earnings (loss) per share are calculated by dividing net earnings (loss) by the weighted average number of common shares and dilutive common stock equivalents outstanding. During the periods when they are anti-dilutive, common stock equivalents, if any, are not considered in the computation. At September 30, 2021 and 2020, there were 6,286,562 and 4,945,134 common share equivalents, respectively. For the three and nine months ended September 30, 2021 and 2020, these potential shares were excluded from the shares used to calculate diluted net earnings per share as their effect would have been antidilutive.

13

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Segments

Operating segments are defined as components of an entity for which separate financial information is available. The Chief Operating Decision Maker (“CODM”) reviews financial information presented on a consolidated basis for the purposes of making operating decisions, allocating resources, and evaluating financial performance. As such, the Company has determined that it operates in one operating and one reportable segment. The Company presents financial information about its operating segment and geographical areas in Note 14 to the condensed consolidated financial statements.

Offering Costs

In connection with the Initial Public Offering (“IPO”), the Company has or will incur accounting, legal and other costs. Such costs will be deferred and recorded as a reduction to stockholders’ equity and recorded against the proceeds from the offering. In the event the offering is aborted, such deferred offering costs will be expensed.

Leases

The Company’s leases are accounted for under FASB ASC Topic 842, “Leases” (“Topic 842”). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right of use assets are recorded based on the present value of lease payments over the expected lease term and adjusted for lease incentives. Lease incentives are recognized when earned and reduce our operating lease asset related to the lease. They are amortized through the operating lease assets as reductions of lease expense over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Options to extend or terminate a lease are included in the calculation of the lease term to the extent that the option is reasonably certain of exercise. The Company has concluded that it is reasonably certain it would exercise such options; therefore, the lease term includes the extension period stated within the lease.

Leases with an initial term of 12 months or less that do contain purchase options or renewal terms that the Company is reasonably certain to exercise are not recorded on the condensed consolidated balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis in the condensed consolidated statement of operations over the lease term.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

14

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Further, Section 102(b) (1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. Private companies are those companies that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, it adopts the new or revised standard at the time private companies adopt the new or revised standard, unless it chooses to early-adopt the new or revised accounting standard. Therefore, the Company’s financial statements may not be comparable to certain public companies.

Recently Adopted Accounting Pronouncements

In November 2019, the FASB issued ASU No. 2019-08 “Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements – Share-Based Consideration Payable to a Customer.” ASU No. 2019-08 amends and clarifies ASU No. 2018-07, which was adopted by the Company on January 1, 2019, to require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. For entities that have already adopted the amendments in ASU No. 2018-07, the amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years, with early adoption permitted. This guidance is applicable to the Company’s fiscal year beginning January 1, 2020. The adoption of this guidance did not have a material impact on its unaudited condensed consolidated financial statements.

In April 2019, the FASB issued ASU No. 2019-04 “Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments.” ASU No. 2019-04 was issued as part of the FASB’s ongoing project to improve upon its ASC, and to clarify and improve areas of guidance related to recently issued standards on credit losses, hedging, and recognition and measurement. This guidance contains several effective dates but is applicable to the Company’s fiscal year beginning January 1, 2020. The adoption of this guidance did not have a material impact on its condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” ASU No. 2019-12 is intended to simplify various aspects related to accounting for income taxes, eliminates certain exceptions to the general principles in ASC Topic 740 related to intra-period tax allocation, simplifies when companies recognize deferred taxes in an interim period, and clarifies certain aspects of the current guidance to promote consistent application. This guidance is effective for public business entities for fiscal years beginning after December 15, 2020, and for interim periods within those fiscal years, with early adoption permitted. This guidance is applicable to the Company’s fiscal year beginning January 1, 2021. The adoption of this guidance did not have a material impact on its condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06.

15

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

ASU 2020-06 also requires that the effect of potential share settlement be included in the diluted EPS calculation when an instrument may be settled in cash or share. This amendment removes current guidance that allows an entity to rebut this presumption if it has a history or policy of cash settlement. Furthermore, ASU 2020-06 requires the application of the if converted method for calculating diluted earnings per share, the treasury stock method will be no longer available. In addition, ASU 2020-06 clarifies that an average market price should be used to calculate the diluted EPS denominator in cases in which the exercise prices may change on the basis of an entity’s share price or changes in the entity’s share price may affect the number of shares that may be used to settle a financial instrument and that an entity should use the weighted-average share count from each quarter when calculating the year-to-date weighted-average share. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU No. 2020-04 provides guidance on optional expedients for a limited time to ease the operational burden in accounting for (or recognizing the effects of) reference rate reform (LIBOR) on financial reporting. This guidance is effective upon the ASUs issuance on March 12, 2020 and companies may elect to apply the amendments prospectively through December 31, 2022. The Company’s credit facilities already contain comparable alternative reference rates that would automatically take effect upon the LIBOR phase out, and it is also reviewing its commercial contracts that may utilize LIBOR as a reference rate. The Company is currently evaluating the potential effects of this guidance on its condensed consolidated financial statements.

NOTE 4 – ACQUISITION

On April 1, 2021, the Company consummated the acquisition of Continental Benefits. According to the Agreement, Continental Benefits was valued, on a cash-free and debt-free basis, at $8.5 million. In addition, pursuant to the Agreement, Marpai Health was valued at an assumed pre-money valuation of the last convertible note’s conversion price of $35 million.

For accounting purposes, the acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination. For the Acquisition, Marpai Health is the accounting acquirer and Continental Benefits is deemed to be the acquired company for financial reporting purposes based on an evaluation of the following facts and circumstances:

1.Marpai Health’s legacy stockholders hold a majority ownership and voting interest in the Company;
2.Marpai Health’s senior management team comprise the senior management of the Company; and
3.Directors appointed by Marpai Health hold a majority of board seats of the Company.

Other factors were considered but they would not change the preponderance of factors indicating that Marpai Health was the accounting acquirer.

16

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 4 – ACQUISITION (CONTINUED)

The following table represents the allocation of the preliminary purchase consideration among the Continental Benefits’ assets acquired and liabilities assumed at their estimated acquisition-date fair values:

Purchase Price

    

  

Equity value

$

13,262,000

Cash acquired

 

(4,762,000)

Total purchase price paid, net of cash acquired

$

8,500,000

Purchase Price Allocation

 

  

Restricted cash

$

6,622,035

Accounts receivable

 

92,231

Prepaid expenses and other current assets

 

131,413

Property and equipment

 

1,601,990

Intangible assets

 

1,010,000

Capitalized software

 

1,230,000

Operating lease - right of use assets

 

1,532,925

Goodwill

 

1,676,239

Trademarks

 

1,860,000

Patents and patent applications

 

700,000

Customer relationships

 

3,370,000

Security deposits

 

54,869

Account payable

 

(925,608)

Accrued expenses

 

(1,267,708)

Accrued fiduciary obligations

 

(4,070,908)

Operating lease liabilities

 

(1,716,246)

Deferred tax liability

 

(2,151,012)

Deferred revenue

 

(1,205,220)

Other long-term liabilities

 

(45,000)

Total fair value of net assets acquired and liabilities assumed

$

8,500,000

The following table summarizes the estimated fair values of Continental Benefits’ identifiable intangible assets, their estimated useful lives and expected amortization periods:

    

Useful

Acquisition

Life in

    

Fair Value

     

Years

Trademarks

$

1,860,000

 

10 Years

Intangible assets

 

1,010,000

 

5 Years

Customer relationships

 

3,370,000

 

7 Years

Patents and patent applications

 

700,000

 

(*)

(*)

Patents which have yet to be approved by US Patent Office. Useful life is determined upon placement into service after approval.

17

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 4 – ACQUISITION (CONTINUED)

The following unaudited pro forma summary presents consolidated information of the Company as if the business combination had occurred on January 1, 2020:

Nine Months Ended

September 30, 2021

Year Ended December

     

(pro forma)

    

31, 2020 (pro forma)

Revenue

$

12,545,844

$

18,388,192

Net loss

 

(12,311,864)

 

(17,620,431)

The pro forma financial information includes adjustments that are directly attributable to the business combination and are factually supportable. The pro forma adjustments include incremental amortization expense of $303,566 related to intangible and tangible assets acquired.

The unaudited pro forma results do not reflect any cost saving synergies from operating efficiencies or the effect of the incremental costs incurred in integrating the two companies.

Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following at:

    

September 30, 2021

    

December 31, 2020

Equipment

$

192,979

$

25,892

Furniture and fixtures

 

341,769

 

76,493

Leasehold improvements

 

416,387

 

190,806

Total cost

 

951,135

 

293,191

Accumulated depreciation

 

(230,543)

 

(97,787)

Property and equipment, net

$

720,592

$

195,404

Depreciation expense was $58,545 and $134,610 for the three and nine months ended September 30, 2021, respectively. Depreciation expense was $18,362 and $56,247 for the three and nine months ended September 30, 2020, respectively.

NOTE 6 – CAPITALIZED SOFTWARE

Capitalized software consists of the following at:

    

September 30, 2021

    

December 31, 2020

Capitalized software

$

7,029,950

$

Accumulated amortization

 

(651,898)

 

Net carrying amount

 

6,378,052

 

Capitalized software in-process

 

239,330

 

3,818,959

Capitalized software, net

$

6,617,382

$

3,818,959

18

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 6 – CAPITALIZED SOFTWARE (CONTINUED)

Amortization expense was $525,345 and $651,898 for the three and nine months ended September 30, 2021.

Estimated amortization for capitalized software for future periods is as follows:

Year Ended December 31,

    

  

2021 (three months)

$

512,138

2022

 

2,044,809

2023

 

2,044,809

2024

 

1,245,818

2025

 

447,762

Thereafter

 

82,716

$

6,378,052

NOTE 7 – INTANGIBLE ASSETS

Intangible assets consist of the following:

September 30, 2021

    

Useful

    

Gross Carrying

    

Accumulated

    

Net Carrying

    

Life

    

Amount

    

Amortization

    

Amount

Trademarks

10 Years

$

1,860,000

$

(93,425)

$

1,766,575

Intangible assets

5 Years

 

1,010,000

 

(101,461)

 

908,539

Customer relationships

7 Years

 

3,370,000

 

(241,813)

 

3,128,187

Patents and patent applications

(*)

 

700,000

 

 

700,000

$

6,940,000

$

(436,699)

$

6,503,301

(*)

Patents which have yet to be approved by US Patent Office. Useful life is determined upon placement into service after approval.

Amortization expense was $218,349 and $436,699 for the three and nine months ended September 30, 2021.

Estimated amortization for intangible assets for future periods is as follows:

Year Ended December 31,

    

  

2021 (three months)

$

217,357

2022

 

869,429

2023

 

869,429

2024

 

869,429

2025

 

869,429

Thereafter

 

2,808,228

$

6,503,301

NOTE 8 – LEASES

EYME leases office space in Tel Aviv, Israel. The lease agreement commenced on May 1, 2019 and expires on June 15, 2021. The lease calls for monthly rent payments of $10,250. EYME exercised an extension option and the lease term was extended for a period of three years, through June 15, 2024, with a 3% increase in base rent.

19

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

On August 1, 2019, EYME entered into sublease with expiration date of May 14, 2021. The sublease calls for monthly rent payments of $2,857 and has been extended for an additional three years, through June 15, 2024.

NOTE 8 – LEASES (CONTINUED)

Continental Benefits leases facilities and equipment under noncancelable operating leases through July 2025.

On January 15, 2021, Continental Benefits entered into sublease with expiration date of November 30, 2023. The sublease calls for monthly rent payments of approximately $14,000 plus tax.

Operating lease expense for the three and nine months ended September 30, 2021 was $186,875 and $407,625, respectively. Operating lease expense for the three and nine months ended September 30, 2020 was $28,503 and $85,509, respectively. Sublease income for the three and nine months ended September 30, 2021 was approximately $54,640 and $115,730, respectively. Sublease income for the three and nine months ended September 30, 2020 was $6,439 and $19,172, respectively.

The Company’s future lease payments, which are presented as current maturities of operating leases and noncurrent operating lease liabilities on the Company’s condensed consolidated balance sheet as of September 30, 2021, including the optional extension, are as follows:

Year Ended December 31,

    

2021 (three months)

$

208,038

2022

 

827,607

2023

 

785,908

2024

 

83,683

2025

 

12,658

Total lease payments

 

1,917,897

Less: imputed interest

 

(176,954)

Present value of lease liabilities

 

1,740,943

Less: current lease liabilities

 

(713,792)

Long-term lease liabilities

$

1,027,148

The remaining lease term, including the optional extension, was 2.3-2.75 years as of September 30, 2021.

The following is a summary as of September 30, 2021, of the expected sublease income:

Year Ended December 31,

    

    

2021 (three months)

$

54,433

2022

 

222,083

2023

 

178,409

2024

 

13,527

Total sublease income

$

468,452

NOTE 9 – SHARE-BASED COMPENSATION

Stock Options

The Company has a Global Stock Incentive Plan (the “Plan”) under which the Company may grant stock options for up to 1,503,421 common shares. Both incentive stock options and non-qualified stock options expire ten years from the date of the grant.

20

Table of Contents`

MARPAI, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

NOTE 9 – SHARE-BASED COMPENSATION (CONTINUED)

The following table summarizes the stock option activity:

Weighted Average 

Aggregate 

Number of 

Weighted Average 

Remaining 

Intrinsic 

    

Options

    

Exercise Price

    

Contractual Term

    

Value

Balance at January 1, 2021

 

468,070

$

0.14

 

9.25

$

1,315,512

Granted

 

1,016,722

 

2.41

 

  

 

  

Forfeited/Cancelled

 

(64,042)

 

0.002

 

  

 

  

Exercised

 

(22,524)

 

0.002

 

  

 

  

Balance at September 30, 2021

 

1,398,226

 

1.80

 

9.22

$

1,095,303

Exercisable at September 30, 2021

 

332,391

$

1.27

 

8.92

$

436,739

    

Weighted Average 

Aggregate 

Number of 

Weighted Average 

Remaining 

Intrinsic 

    

Options

    

Exercise Price

    

Contractual Term

    

Value

Balance at January 1, 2020

 

$

 

 

Granted

 

468,070

 

0.14

 

  

 

  

Forfeited/Cancelled

 

 

 

  

 

  

Exercised

 

 

 

  

 

  

Balance at September 30, 2020

 

468,070

 

0.14

 

9.50

$

932,288

Exercisable at September 30, 2020

 

33,294

$

0.002

 

9.50

$

70,886

The following table summarizes the Company’s non-vested stock options:

Weighted-Average 

Non-vested Options 

Grant Date Fair

    

Outstanding

    

 Value

At January 1, 2021

427,035

$

1.21

Options granted

 

1,016,722

 

0.99

Options forfeited/cancelled

 

(64,042)

 

1.88

Options exercised

 

(22,524)

 

1.41

Options vested

 

(291,356)

 

0.97

At September 30, 2021

 

1,065,835